Letter to Shareholders, Notice of AGM & Proxy Form
Released
Released
Announcement PDF
12 October 2023
Dear Shareholder
Upcoming Annual General Meeting of Shareholders
The Company’s Annual General Meeting is scheduled to be held on Monday, 13 November 2023 at 11:00 am (AEDT)
(Meeting)
In accordance with section 249R of the Corporations Act 2001 (Cth) (Corporations Act), as amended under the Corporations
Amendment (Meetings and Documents) Act 2022 (Cth), and rule 12.23 of the Company's constitution, Shareholders will be
given the opportunity to attend and participate in a general meeting held at a physical location. The Meeting cannot be
accessed virtually.
The Company strongly encourages Shareholders to lodge a directed proxy form by Saturday, 11 November 2023 at 11.30
am (AEDT). Questions should also be submitted in advance of the Meeting as this will provide management with the best
opportunity to prepare for the Meeting, for example by preparing answers in advance to Shareholders’ questions. However,
votes and questions may also be submitted during the Meeting. Further details of how to participate in the Meeting are set
out in the Notice of Meeting.
The Notice of Meeting and Annual Report can be viewed and downloaded from: https://cynata.com/cyp-asx-announcements
Shareholders who have nominated an email address and have elected to receive electronic communications from the
Company, will receive an email to their nominated email address with a link to an electronic copy of the important Meeting
documents.
In accordance with sections 110C-110K the Corporations Act, as amended by the Corporations Amendment (Meetings and
Documents) Act 2022 (Cth), no hard copy of the Notice of Annual General Meeting and Explanatory Memorandum will be
circulated, unless a shareholder has requested a hard copy.
If you are unable to access any of the important Meeting documents online or if you wish to receive a hard copy of the
Meeting documents please contact our share registry, Automic, on 1300 288 664 (within Australia) or +612 9698 5414 or via
email at hello@automic.coim.au
Your right to elect to receive documents electronically or in hard copy
Cynata Therapeutics will no longer send a hard copy of the meeting documents unless a shareholder requests a copy to be
mailed.
We encourage all shareholders to provide an email address so that we can send investor communications electronically when
they become available online, which includes items such as meeting documents and annual reports.
Shareholders can still elect to receive some or all of their communications in hard copy or electronic form or elect not to
receive certain documents such as annual reports.
To review your communications preferences or sign up to receive your shareholder communications via email, please
update your communication preferences at https://investor.automic.com.au/.
If you are a shareholder and would like a hard copy of a communication, need further information about the options available
to you or have questions about your holding, visit https://investor.automic.com.au/ or contact our share registry:
Telephone (within Australia): 1300 288 664
Telephone (outside Australia): +61 2 9698 5414
Email: hello@automicgroup.com.au
Website: https://investor.automic.com.au/
Dr Kilian Kelly, Managing Director & CEO
CONTACTS:
Dr Kilian Kelly, MD & CEO, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, littlebigdealconsulting@gmail.com
Cynata Therapeutics Limited
Level 3, 100 Cubitt Street, Cremorne, Victoria, 3121, Australia
T: +613 7067 6940 E: info@cynata.com
ABN – 98 104 037 372
CYNATA THERAPEUTICS LIMITED
ACN 104 037 372
NOTICE OF ANNUAL GENERAL MEETING
The Annual General Meeting of the Company will be convened at Amora Hotel
Riverwalk Melbourne, 649 Bridge Road, Richmond VIC 3121 on 13 November
2023 at 11.00 am (AEDT).
This Notice of Annual General Meeting should be read in its entirety. If Shareholders are in doubt as to
how they should vote, they should seek advice from their accountant, solicitor or other professional adviser
prior to voting.
Should you wish to discuss any matter please do not hesitate to contact the Company Secretary by
telephone on +61 8 6377 8043.
CYNATA THERAPEUTICS LIMITED
ACN 104 037 372
NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given that the annual general meeting of Shareholders of Cynata Therapeutics Limited
(Company) will held at Amora Hotel Riverwalk Melbourne, 649 Bridge Road, Richmond VIC 3121 on
13 November 2023 at 11.00 am (AEDT) (Meeting).
The Explanatory Memorandum to this Notice provides additional information on matters to be considered
at the Meeting. The Explanatory Memorandum also forms part of this Notice.
The Directors have determined pursuant to regulation 7.11.37 of the Corporations Regulations 2001 (Cth)
that the persons eligible to vote at the Meeting are those who are registered as Shareholders on
11 November 2023 at 7.00 pm (AEDT).
Terms and abbreviations used in this Notice and Explanatory Memorandum are defined in Section 10 of
the Explanatory Memorandum.
AGENDA
Annual Report
To table and consider the Annual Report of the Company and its controlled entities for the year
ended 30 June 2023, which includes the Financial Report, the Directors' Report and the Auditor's
Report.
1.
Resolution 1 – Adoption of Remuneration Report
To consider and, if thought fit, to pass, with or without amendment, the following resolution as
an ordinary resolution:
"That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the
Remuneration Report be adopted."
Note: The vote on this Resolution is advisory only and does not bind the Directors or the
Company.
2.
Resolution 2 – Re-election of Dr Darryl Maher as a Director
To consider and, if thought fit, to pass with or without amendment, the following resolution as
an ordinary resolution:
"That Dr Darryl Maher, who retires in accordance with Listing Rule 14.4 and rule 8.1(d) of the
Constitution, being eligible and offering himself for re-election, is re-elected as a Director."
3.
Resolution 3 – Approval of 10% Placement Facility
To consider and, if thought fit, to pass with or without amendment, the following resolution as
a special resolution:
"The Company have the additional capacity to issue equity securities provided for in Listing Rule
7.1A."
1
4.
Resolution 4 – Approval of Issue of Equity Securities under
Employee Incentive Plan
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 7.2 Exception 13(b), and for all other purposes, approval
is given for the issue of securities under the “Cynata Equity Incentive Plan”, on the terms and
conditions set out in the Explanatory Memorandum.”
Note: A voting exclusion applies to this Resolution.
5.
Resolution 5 – Approval of issue of Options to Dr Geoff Brooke
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“The issue of 500,000 Options to Dr Geoff Brooke (or nominee), details of which are set out in
the Explanatory Memorandum, is approved under and for the purpose of Listing Rule 10.14 and
for all other purposes.”
Note: A voting exclusion applies to this Resolution.
6.
Resolution 6 – Approval of issue of Options to Dr Paul Wotton
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“The issue of 220,000 Options to Dr Paul Wotton (or nominee), details of which are set out in the
Explanatory Memorandum, is approved under and for the purpose of Listing Rule 10.14 and for
all other purposes.”
Note: A voting exclusion applies to this Resolution.
7.
Resolution 7 – Approval of issue of Options to Ms Janine Rolfe
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“The issue of 220,000 Options to Ms Janine Rolfe (or nominee), details of which are set out in the
Explanatory Memorandum, is approved under and for the purpose of Listing Rule 10.14 and for
all other purposes.”
Note: A voting exclusion applies to this Resolution.
8.
Resolution 8 – Approval of issue of Options to Dr Darryl Maher
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“The issue of 220,000 Options to Dr Darryl Maher (or nominee), details of which are set out in
the Explanatory Memorandum, is approved under and for the purpose of Listing Rule 10.14 and
for all other purposes.”
Note: A voting exclusion applies to this Resolution.
2
9.
Resolution 9 – Approval of issue of Options to Dr Kilian Kelly
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“The issue of 750,000 Options to Dr Kilian Kelly (or nominee), details of which are set out in the
Explanatory Memorandum, is approved under and for the purpose of Listing Rule 10.14 and for
all other purposes.”
Note: A voting exclusion applies to this Resolution.
10.
Resolution 10 – Renewal of Proportional Takeover Approval
Provisions
To consider and, if thought fit, to pass the following resolution as a special resolution:
“That, for the purpose of sections 136(2) and 648G(4) of the Corporations Act and for all other
purposes, the proportional takeover approval provisions in rule 6 of the Company’s Constitution
be renewed for a period of three years from the date of this Meeting.”
11.
Voting exclusions
The Company will disregard any votes cast on Resolutions 1, 4, 5, 6, 7, 8 or 9 in contravention of
sections 250BD or 250R of the Corporations Act.
In accordance with the Listing Rule 14.11, the Company will disregard votes cast in favour of the
following Resolutions by or on behalf of:
Resolution
Resolution 4 – Approval of
Issue of Equity Securities
under Cynata Equity
Incentive Plan
Resolutions 5 to 9 –
Approval of issue of
Options to Directors
under the Incentive Plan
Person excluded from voting
A person who is eligible to participate in the Plan and any of their
Associates.
Each of the Directors of the Company, their nominees(s), any other
person who will obtain a material benefit as a result of the issue of
securities in accordance with these Resolutions, any other person
referred to in ASX Listing Rules 10.14.1, 10.14.2 or 10.14.3 who is
eligible to participate in the Plan and any of their Associates.
However, the Company need not disregard votes cast in favour of the above Resolutions if the
vote is cast by:
(a)
a person as proxy or attorney for a person who is entitled to vote on the resolution,
in accordance with the directions given to the proxy or attorney to vote on the
resolution in that way; or
(b)
the person chairing the Meeting as proxy or attorney for a person who is entitled to
vote on the resolution, in accordance with the direction given to the chair to vote as
the chair decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on
behalf of a beneficiary provided the provided the following conditions are met:
(i)
the beneficiary provides written confirmation to the holder that the
beneficiary is not excluded from voting, and is not an Associate of a person
excluded from voting, on the resolution; and
3
(ii)
12.
the holder votes on the resolution in accordance with the directions given
by the beneficiary to the holder to vote in that way.
Express authorisation of the Chair
If a Shareholder appoints the Chair as their proxy, or the Chair is appointed as the Shareholder’s
proxy by default, and the Shareholder does not mark a voting box for Resolutions 1, 4, 5, 6, 7, 8
or 9, then by submitting the appointment the Shareholder expressly authorises the Chair to
exercise the proxy in respect of the relevant Resolution as they decide, even though the
Resolution is connected with the remuneration of one or more of the Company’s Key
Management Personnel. The Chair intends to vote all available proxies in favour of all
Resolutions.
Dated 9 October 2023
BY ORDER OF THE BOARD
Mr Peter Webse
Company Secretary
4
CYNATA THERAPEUTICS LIMITED
ACN 104 037 372
EXPLANATORY MEMORANDUM
1.
Introduction
This Explanatory Memorandum has been prepared for the information of Shareholders in
connection with the business to be conducted at the Meeting to be convened at Amora Hotel
Riverwalk Melbourne, 649 Bridge Road, Richmond VIC 3121 on 13 November 2023 at 11.00 am
(AEDT).
This Explanatory Memorandum should be read in conjunction with and forms part of the
accompanying Notice. The purpose of this Explanatory Memorandum is to provide information
to Shareholders in deciding whether or not to pass the Resolutions set out in the Notice.
2.
Action to be taken by Shareholders
Shareholders should read the Notice and this Explanatory Memorandum carefully before
deciding how to vote on the Resolutions.
2.1
Proxies
Please note that:
(a)
a member of the Company entitled to attend and vote at the Meeting is entitled to
appoint a proxy;
(b)
a proxy need not be a member of the Company; and
(c)
a member of the Company entitled to cast two or more votes may appoint two proxies
and may specify the proportion or number of votes each proxy is appointed to
exercise, but where the proportion or number is not specified, each proxy may exercise
half of the votes.
Proxy votes can be lodged online at https://investor.automic.com.au/#/loginsah. Alternatively,
any proxy appointment documents may be provided:
(a)
In Person – Automic, Level 5, 126 Phillip Street, Sydney NSW 2000;
(b)
By Mail – Automic, GPO Box 5193, Sydney NSW 2001;
(c)
By Email – meetings@automicgroup.com.au; or
(d)
By Facsimile – +61 (0)2 8583 3040.
Proxy appointments must be received by 11 November 2023 at 11.00 am (AEDT), being not later
than 48 hours before the commencement of the Meeting. Any proxy appointments received
after that time will not be valid for the Meeting (unless otherwise determined by the Board).
Should you wish to discuss the matters in this Notice of Meeting please do not hesitate to
contact the Company Secretary on +61 8 6377 8043.
3.
Annual Report
Shareholders will be offered the opportunity to discuss the Annual Report at the Meeting.
Copies of the Annual Report can be found on the Company’s website www.cynata.com or by
contacting the Company Secretary on +61 8 6377 8043.
There is no requirement for Shareholders to approve the Annual Report.
5
In addition to being offered the opportunity to discuss the Annual Report, Shareholders will be
able to:
(a)
ask questions or make comment on the management of the Company; and
(b)
ask the auditor questions about the conduct of the audit and the preparation and
content of the Auditor's Report.
In addition to taking questions at the Meeting, written questions to the Chair about the
management of the Company, or to the Company's auditor about:
(a)
the preparation and the content of the Auditor's Report;
(b)
the conduct of the audit;
(c)
accounting policies adopted by the Company in relation to the preparation of the
financial statements; and
(d)
the independence of the auditor in relation to the conduct of the audit,
may be submitted no later than 5 Business Days before the Meeting to the Company Secretary
at the Company's registered office.
4.
Resolution 1 – Adoption of Remuneration Report
Section 250R(2) of the Corporations Act provides that the Company is required to put the
Remuneration Report to a vote of Shareholders. The Directors' Report contains a Remuneration
Report which sets out the remuneration policy for the Company and reports the remuneration
arrangements in place for the executive and non-executive directors.
Section 250R(3) of the Corporations Act provides that this Resolution is advisory only and does
not bind the Directors of the Company. Of itself, a failure of Shareholders to pass this Resolution
will not require the Directors to alter any of the arrangements in the Remuneration Report.
However, under sections 250U and 250Y of the Corporations Act, Shareholders have the
opportunity to remove the Board if the Remuneration Report receives a 'no' vote of 25% or more
at two consecutive annual general meetings (Two Strikes Rule).
Under the Two Strikes Rule, where a resolution on the Remuneration Report receives a 'no' vote
of 25% or more at two consecutive annual general meetings, the Company will be required to
put to Shareholders at the second annual general meeting, a resolution on whether another
meeting should be held (within 90 days) at which all Directors (other than the Managing
Director) who were in office at the date of approval of the applicable Directors' Report must
stand for re-election.
At the Company’s 2022 Annual General Meeting the remuneration report was approved by over
75% of Shareholders present and voting.
In summary, if the Remuneration Report receives a 'no' vote of 25% or more at this Meeting,
Shareholders should be aware that if there is a 'no' vote of 25% or more at the next annual
general meeting, the consequences are that all Directors (other than the Managing Director)
may be up for re-election.
The Chair will allow a reasonable opportunity for Shareholders as a whole to ask about, or make
comments on the Remuneration Report.
The Chair intends to exercise all undirected proxies in favour of Resolution 1. If the Chair of the
Meeting is appointed as your proxy and you have not specified the way the Chair is to vote on
Resolution 1, by appointing the Chair as proxy, you are considered to have provided the Chair
with an express authorisation for the Chair to vote the proxy in accordance with the Chair’s
intention.
6
5.
Resolution 2 – Re-election of Dr Darryl Maher as a Director
5.1
Background
Under Listing Rule 14.4 and rule 8.1(d) of the Company’s Constitution, a director must not hold
office (without re-election) past the third annual general meeting following the director’s
appointment or 3 years, whichever is longer.
Dr Darryl Maher was re-elected at the Company’s 2020 Annual General Meeting, meaning this
is the third annual general meeting since his last re-election. Accordingly, Dr Maher retires by
rotation at this Meeting and, being eligible, seeks re-election.
5.2
Biography of Dr Maher
Dr Maher joined the Cynata Board in June 2020 following over 20 years in the pharmaceutical
industry as a senior R&D Executive at CSL Limited. His most recent position was Vice President
of R&D and Medical Affairs at CSL Behring Australia where he was responsible for the
development of multiple successful drug products from initiation through clinical development
and ultimately to commercialisation. Dr Maher undertook medical training, qualified as a
specialist haematologist and completed a PhD before commencing his career in the
pharmaceutical industry. He was a former President of the Australian Pharmaceutical Physicians
Association and a director of Vaccine Solutions. He earned his Bachelor of Medicine/Surgery
from the University of Melbourne, Australia and undertook his PhD at The Walter and Eliza Hall
Institute of Medical Research. He is a retired Fellow of both the Royal Australian College of
Physicians and the Royal College of Pathologists of Australia.
5.3
Recommendation
Resolution 2 is an ordinary resolution.
The Board (other than Dr Maher) unanimously supports the re-election of Dr Maher.
The Chair of the Meeting intends to vote undirected proxies in favour of Resolution 2.
6.
Resolution 3 – Approval of 10% Placement Facility
6.1
General
Listing Rule 7.1A enables eligible entities to seek approval of Shareholders by special resolution
to have the capacity to issue Equity Securities up to 10% of its issued share capital through
placements over a 12-month period after the annual general meeting (10% Placement Facility).
The 10% Placement Facility is in addition to the Company's 15% placement capacity under Listing
Rule 7.1.
6.2
ASX Listing Rule 7.1A
Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of
equity securities that a listed company can issue without the approval of its shareholders over
any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of
that period.
Under Listing Rule 7.1A, an eligible entity can seek approval from its members by way of a special
resolution passed at its annual general meeting, to increase this 15% limit by an extra 10% to
25% for the 12 months following that meeting.
An ‘eligible entity’ means an entity which is not included in the S&P/ASX 300 and which has a
market capitalisation of $300 million or less. The Company is an eligible entity for these
purposes.
7
Resolution 3 seeks Shareholder approval by way of special resolution for the Company to have
the additional 10% capacity provided for in Listing Rule 7.1A to issue equity securities without
further Shareholder approval.
If Resolution 3 is passed, the Company will be able to issue equity securities up to the combined
25% limit in Listing Rules 7.1 and 7.1A without any further Shareholder approval.
If Resolution 3 is not passed, the Company will not be able to access the additional 10% capacity
to issue equity securities without Shareholder approval provided for in Listing Rule 7.1A and will
remain subject to the 15% limit on issuing equity securities without Shareholder approval set
out in Listing Rule 7.1.
6.3
Further requirements of Listing Rule 7.1A
(a)
Shareholder approval
The ability to issue Equity Securities under the 10% Placement Facility is subject to
shareholder approval by way of a special resolution at an annual general meeting.
(b)
Equity Securities
Any Equity Securities issued under the 10% Placement Facility must be in the same
class as an existing quoted class of Equity Securities of the Company.
The Company, as at the date of the Notice, has on issue one class of quoted Equity
Securities, being the Shares (ASX Code: CYP).
(c)
Formula for calculating 10% Placement Facility
Listing Rule 7.1A.2 provides that eligible entities which have obtained shareholder
approval at an annual general meeting may issue or agree to issue, during the 10%
Placement Period, a number of Equity Securities calculated in accordance with the
following formula:
(A x D) – E
Where:
A
is the number of shares on issue 12 months before the date of issue or
agreement:
(A)
plus the number of fully paid shares issued in the 12 months under
an exception in Listing Rule 7.2;
(B)
plus the number of partly paid shares that became fully paid in the
12 months;
(C)
plus the number of fully paid shares issued in the 12 months with
approval of holders of shares under Listing Rule 7.1 and 7.4. This
does not include an issue of fully paid shares under the entity's 15%
placement capacity without shareholder approval;
(D)
less the number of fully paid shares cancelled in the 12 months.
Note that A has the same meaning in Listing Rule 7.1 when calculating an
entity's 15% placement capacity.
D
is 10%
E
is the number of Equity Securities issued or agreed to be issued under Listing
Rule 7.1A.2 in the 12 months before the date of the issue or agreement to
issue that are not issued with the approval of shareholders under Listing Rule
7.1 or 7.4.
8
(d)
Listing Rule 7.1 and Listing Rule 7.1A
The ability of an entity to issue Equity Securities under Listing Rule 7.1A is in addition
to the entity's 15% placement capacity under Listing Rule 7.1.
The actual number of Equity Securities that the Company will have capacity to issue
under Listing Rule 7.1A will be calculated at the date of issue of the Equity Securities
in accordance with the formula prescribed in Listing Rule 7.1A.2 (refer to Section 6.3(c)
above).
(e)
Minimum Issue Price
The issue price of Equity Securities issued under Listing Rule 7.1A must be not less than
75% of the VWAP of Equity Securities in the same class calculated over the 15 Trading
Days in which trades in that class were recorded immediately before:
(i)
the date on which the price at which the Equity Securities are to be issued is
agreed; or
(ii)
if the Equity Securities are not issued within ten Trading Days of the date in
paragraph (i) above, the date on which the Equity Securities are issued,
(Minimum Issue Price).
(f)
10% Placement Period
Shareholder approval of the 10% Placement Facility under Listing Rule 7.1A is valid
from the date of the annual general meeting at which the approval is obtained and
expires on the first to occur of the following:
(i)
the date that is 12 months after the date of the annual general meeting at
which the approval is obtained (which, in the case of Resolution 3, will be
13 November 2024);
(ii)
the time and date of the Company’s 2024 annual general meeting; or
(iii)
the date of the approval by shareholders of a transaction under Listing Rules
11.1.2 (a significant change to the nature or scale of activities) or 11.2
(disposal of main undertaking),
(10% Placement Period).
6.4
Specific information required by Listing Rule 7.3A
Pursuant to and in accordance with Listing Rule 7.3A, information is provided in relation to the
approval of the 10% Placement Facility as follows:
(a)
The 10% Placement Period is as set out in section 6.3(f) above.
(b)
The Equity Securities will be issued at an issue price of not less than the Minimum Issue
Price (defined above).
(c)
If Resolution 3 is approved by Shareholders and the Company issues Equity Securities
under the 10% Placement Facility, the existing Shareholders' voting power in the
Company will be diluted as shown in the below table. Current Shareholders should be
aware that there is a risk of economic and voting dilution that may result from an issue
of Equity Securities under the 10% Placement Facility, including the risk that:
(i)
the market price for the Company's Equity Securities may be significantly
lower on the date of the issue of the Equity Securities than on the date of
the Meeting; and
(ii)
the Equity Securities may be issued at a price that is at a discount to the
market price for the Company's Equity Securities on the issue date or the
9
Equity Securities are issued as part of consideration for the acquisition of a
new asset,
which may have an effect on the amount of funds raised by the issue of the Equity
Securities.
The table below shows the dilution of existing Shareholders on the basis of the current
market price of Shares and the current number of ordinary securities for variable "A"
calculated in accordance with the formula in Listing Rule 7.1A(2) as at the date of this
Notice.
The table also shows:
(i)
two examples where variable “A” has increased, by 50% and 100%. Variable
“A” is based on the number of ordinary securities the Company has on issue.
The number of ordinary securities on issue may increase as a result of issues
of ordinary securities that do not require Shareholder approval (for example,
a pro rata entitlements issue or scrip issued under a takeover offer) or future
specific placements under Listing Rule 7.1 that are approved at a future
Shareholders’ meeting; and
(ii)
two examples of where the issue price of ordinary securities has decreased
by 50% and increased by 100% as against the current market price.
Dilution
Variable ‘A’ in
Listing Rule
7.1A2
Current
Variable A
179,631,786
Shares
50% increase
in current
Variable A
269,447,679
Shares
100% increase
in current
Variable A
359,263,572
Shares
$0.065
$0.13
$0.26
50% decrease in
Issue Price
Issue Price
100% increase in Issue
Price
10%
voting
dilution
17,963,178
17,963,178
17,963,178
Funds
raised
$1,167,606
$2,335,213
$4,670,426
10%
voting
dilution
26,944,767
26,944,767
26,944,767
Funds
raised
$1,751,409
$3,502,819
$7,005,639
10%
voting
dilution
35,926,357
35,926,357
35,926,357
Funds
raised
$2,335,213
$4,670,416
$9,340,852
The table has been prepared on the following assumptions:
(i)
The Company issues the maximum number of Equity Securities available under the 10%
Placement Facility.
(ii)
No Options are exercised into Shares before the date of the issue of the Equity Securities.
10
(iii)
The 10% voting dilution reflects the aggregate percentage dilution against the issued Share
capital at the time of issue. This is why the voting dilution is shown in each example as 10%.
(iv)
The table does not show an example of dilution that may be caused to a particular Shareholder
by reason of placements under the 10% Placement Facility, based on that Shareholder’s
holding at the date of the Meeting.
(v)
The table shows only the effect of issues of Equity Securities under Listing Rule 7.1A, not under
the 15% placement capacity under Listing Rule 7.1.
(vi)
The issue of Equity Securities under the 10% Placement Facility consists only of Shares.
(vii)
At the date of this Notice, there are currently 179,631,786 Shares on issue.
(viii)
The issue price is $0.13, being the closing price of the Shares on 6 October 2023.
(d)
The Company will only issue the Equity Securities during the 10% Placement Period.
(e)
The Company may seek to issue the Equity Securities for cash consideration in order
to raise funds for expanding or accelerating the Company’s existing business activities
(including expenses associated with further tests in relation to the Company’s existing
projects), pursuing other acquisitions that have a strategic fit or will otherwise add
value to Shareholders (including expenses associated with such acquisitions) and
general working capital.
(f)
The Company will comply with the disclosure obligations under Listing Rule 7.1A(4)
upon issue of any Equity Securities.
(g)
The Company’s allocation policy is dependent on the prevailing market conditions at
the time of any proposed issue pursuant to the 10% Placement Facility. The identity of
the recipients of Equity Securities will be determined on a case-by-case basis having
regard to the factors including but not limited to the following:
(i)
the purpose of the issue;
(ii)
the methods of raising funds that are av
Share your feedback
Discover